SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02596113

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer

The investigators designed a prospective study to evaluate the predictive ability of detection of mutations in genes involved in carcinogenesis of the colon (eg hMLH1, K-Ras, B-Raf, ccfDNA) in a sample of Greek population presents for conducting colonoscopy in the context of screening under international CRC prevention instructions. This investigation will be carried out in individuals in normal risk in order to study specific mutations (in blood and tissue) to draw reliable conclusions about whether we can detect (with greater sensitivity and specificity) patients with precancerous lesions or CRC with a simple blood test thereby reducing the cost and side effects of repeated endoscopic procedures.

NCT02596113 Colorectal Cancer
MeSH:Colorectal Neoplasms
HPO:Neoplasm of the large intestine


Primary Outcomes

Measure: Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with no endoscopic findings

Time: 1 month

Measure: Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with adenomatous polyp bigger than 1 cm

Time: 1 month

Measure: Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion

Time: 1 month

Time Perspective: Prospective

Case-Control


There is one SNP

SNPs


1 V600E

From all these three populations, samples would be collected from peripheral blood (plasma) and colon tissue biopsy (normal or abnormal, respectively) in order to find a possible common mutations of some genes involved in the pathogenesis of the CRC in these 3 groups [e.g. in KRAS12, 13, 61, BRAF (V600E), ccfDNA some point mutations in hMLH1]. --- V600E ---



HPO Nodes


HPO: